47 research outputs found

    Zinc-mediated inhibition of human α<sub>1</sub>β<sub>2</sub> and α<sub>1</sub>β<sub>2</sub>γ<sub>2S</sub> GABA<sub>A</sub>R signalling in <i>Xenopus</i> oocytes.

    No full text
    <p>(A) Representative trace of the inhibition mediated 100 μM Zn<sup>2+</sup> of the currents elicited by 10 μM GABA (EC<sub>80</sub>) through the α<sub>1</sub>β<sub>2</sub> GABA<sub>A</sub>R. (B) Representative trace of the inhibition mediated 100 μM Zn<sup>2+</sup> of the currents induced by 100 μM GABA (EC<sub>80</sub>) through the α<sub>1</sub>β<sub>2</sub>γ<sub>2S</sub> GABA<sub>A</sub>R. (C) The degree of inhibition mediated by 100 μM Zn<sup>2+</sup> of GABA EC<sub>80</sub>-evoked currents in oocytes expressing α<sub>1</sub>β<sub>2</sub> mean ± S.E.M.; 77 ± 6.3%; N = 7and α<sub>1</sub>β<sub>2</sub>γ<sub>2S</sub> (mean ± S.E.M.; 4.7 ± 4.6%; N = 6) GABA<sub>A</sub>Rs.</p

    Functional properties of GABA at six human GABA<sub>A</sub>Rs expressed in <i>Xenopus</i> oocytes.

    No full text
    <p>Concentration-response curves of GABA at the α<sub>1</sub>β<sub>2</sub>γ<sub>2S</sub> (circle), α<sub>2</sub>β<sub>2</sub>γ<sub>2S</sub> (square), α<sub>3</sub>β<sub>2</sub>γ<sub>2S</sub> (triangle), α<sub>5</sub>β<sub>2</sub>γ<sub>2S</sub> (inverted triangle), α<sub>6</sub>β<sub>2</sub>δ (diamond) and α<sub>6</sub>β<sub>2</sub> (asterisk) GABA<sub>A</sub>Rs (means ± S.E.M.; N = 4–7).</p

    Comparison of the functional efficacies of clobazam, <i>N</i>-desmethylclobazam, and clonazepam at α<sub>1,2,3,5</sub>β<sub>2</sub>γ<sub>2S</sub> GABA<sub>A</sub>Rs with those of diazepam and zolpidem.

    No full text
    <p>(A) Potentiation of the response elicited by GABA EC<sub>20</sub> by 3 μM diazepam in Xenopus oocytes injected with cRNAs encoding for α<sub>1</sub>β<sub>2</sub>γ<sub>2S</sub>, α<sub>2</sub>β<sub>2</sub>γ<sub>2S</sub>, α<sub>3</sub>β<sub>2</sub>γ<sub>2S</sub> and α<sub>5</sub>β<sub>2</sub>γ<sub>2S</sub> GABA<sub>A</sub>Rs in a subunit ratio of 1:1:1 (means ± S.E.M.; N = 2–4) (B) Potentiation of the response elicited by EC<sub>20</sub> GABA by 3 μM clobazam and 3 μM zolpidem in Xenopus oocytes injected with cRNAs encoding the α<sub>2</sub>β<sub>2</sub>γ<sub>2S</sub> GABA<sub>A</sub>R injected in a subunit ratio of 1:1:5 (means ± S.E.M.; N = 2).</p

    . Functional properties of clobazam, <i>N</i>-desmethylclobazam and clonazepam at the human α<sub>6</sub>β<sub>2</sub>δ and α<sub>6</sub>β<sub>2</sub> GABA<sub>A</sub>Rs expressed in <i>Xenopus</i> oocytes.

    No full text
    <p>(A) Representative traces for various concentrations of clobazam (top), <i>N</i>-desmethylclobazam (middle) and clonazepam (bottom) co-applied with GABA EC<sub>20</sub> to oocytes expressing the α<sub>6</sub>β<sub>2</sub>δ GABA<sub>A</sub>R. The black bars represent applications of GABA EC<sub>20</sub> and of 300 M GABA that elicits maximal current through the receptor. The grey bars represent applications of various concentrations of clobazam, <i>N</i>-desmethylclobazam or clonazepam (a 30 s pre-incubation with the compound followed by co-application of the compound and GABA EC<sub>20</sub>). (B) Concentration-response relationships for clobazam (top), <i>N</i>-desmethylclobazam (middle) and clonazepam (bottom) at the α<sub>6</sub>β<sub>2</sub>δ GABA<sub>A</sub>R and for <i>N</i>-desmethylclobazam at the α<sub>6</sub>β<sub>2</sub> GABA<sub>A</sub>R (middle) in the presence of GABA EC<sub>20</sub> (means ± S.E.M.; N = 4–6).</p

    Chemical structures of clobazam, <i>N</i>-desmethylclobazam and clonazepam.

    No full text
    <p>Chemical structures of clobazam, <i>N</i>-desmethylclobazam and clonazepam.</p

    Discovery and Structure–Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5‑HT<sub>2A</sub> Receptor Agonists

    No full text
    Classical psychedelics such as psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT) are showing promising results in clinical trials for a range of psychiatric indications, including depression, anxiety, and substance abuse disorder. These compounds are characterized by broad pharmacological activity profiles, and while the acute mind-altering effects can be ascribed to their shared agonist activity at the serotonin 2A receptor (5-HT2AR), their apparent persistent therapeutic effects are yet to be decidedly linked to activity at this receptor. We report herein the discovery of 2,5-dimethoxyphenylpiperidines as a novel class of selective 5-HT2AR agonists and detail the structure–activity investigations leading to the identification of LPH-5 [analogue (S)-11] as a selective 5-HT2AR agonist with desirable drug-like properties

    Discovery and Structure–Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5‑HT<sub>2A</sub> Receptor Agonists

    No full text
    Classical psychedelics such as psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT) are showing promising results in clinical trials for a range of psychiatric indications, including depression, anxiety, and substance abuse disorder. These compounds are characterized by broad pharmacological activity profiles, and while the acute mind-altering effects can be ascribed to their shared agonist activity at the serotonin 2A receptor (5-HT2AR), their apparent persistent therapeutic effects are yet to be decidedly linked to activity at this receptor. We report herein the discovery of 2,5-dimethoxyphenylpiperidines as a novel class of selective 5-HT2AR agonists and detail the structure–activity investigations leading to the identification of LPH-5 [analogue (S)-11] as a selective 5-HT2AR agonist with desirable drug-like properties

    Semisynthetic Analogues of Toxiferine I and Their Pharmacological Properties at α7 nAChRs, Muscle-Type nAChRs, and the Allosteric Binding Site of Muscarinic M<sub>2</sub> Receptors

    No full text
    A new series of analogues of the calabash curare alkaloid toxiferine I was prepared and pharmacologically evaluated at α7 and muscle-type nAChRs and the allosteric site of muscarinic M<sub>2</sub> receptors. The new ligands differ from toxiferine I by the absence of one (<b>2a</b>–<b>c</b>) or two (<b>3a</b>–<b>c</b>) hydroxy groups, saturation of the exocyclic double bonds, and various N-substituents (methyl, allyl, 4-nitrobenzyl). At the muscle-type nAChRs, most ligands showed similar binding to the muscle relaxant alcuronium, indicating neuromuscular blocking activity, with the nonhydroxylated analogues <b>3b</b> (<i>K</i><sub>i</sub> = 75 nM) and <b>3c</b> (<i>K</i><sub>i</sub> = 82 nM) displaying the highest affinity. At α7 nAChRs, all ligands showed a moderate to low antagonistic effect, suggesting that the alcoholic functions are not necessary for antagonistic action. Compound <b>3c</b> exerted the highest preference for the muscle-type nAChRs (<i>K</i><sub>i</sub> = 82 nM) over α7 (IC<sub>50</sub> = 21 μM). As for the allosteric site of M<sub>2</sub> receptors, binding was found to be dependent on N-substitution rather than on the nature of the side chains. The most potent ligands were the <i>N</i>-allyl analogues <b>2b</b> and <b>3b</b> (EC<sub>0.5,diss</sub> = 12 and 36 nM) and the <i>N</i>-nitrobenzyl derivatives <b>2c</b> and <b>3c</b> (EC<sub>0.5,diss</sub> = 32 and 49 nM). The present findings should help delineate the structural requirements for activity at different types of AChRs and for the design of novel selective ligands

    Changes in cortical network activity induced by 7–9 cumulatively increasing concentrations of the functionally selective δ-GABA<sub>A</sub>R agonists THIP and Thio-THIP.

    No full text
    <p>The heat maps present statistically significant changes in 40 activity parameters relative to native activity (no drug, 100%) (Student’s paired t-test, p≤0.05). The concentration-response relationships for the drugs at 10 selected activity parameters are given as mean ± S.E.M. relative to native activity (no drug, 100%).</p
    corecore